Champions Oncology (CSBR) Total Current Liabilities (2011 - 2026)
Champions Oncology (CSBR) posted quarterly Total Current Liabilities of $19.9 million for Q2 2026, down 16.48% year-over-year from $23.9 million in Q2 2025, and down 3.65% quarter-over-quarter from $20.7 million in Q1 2026.
Champions Oncology (CSBR) Total Current Liabilities (2011 - 2026) Analysis & Trends
Champions Oncology's Total Current Liabilities history runs 16 years deep, the most recent figure standing at $19.9 million for Q2 2026.
- In Q2 2026, Total Current Liabilities fell 16.48% year-over-year to $19.9 million; the TTM figure through Apr 2026 stood at $19.9 million (down 16.48% YoY), while the FY2026 annual figure was $19.9 million, down 16.48% from the prior year.
- Total Current Liabilities for Q2 2026 stood at $19.9 million, down from $20.7 million in the prior quarter.
- The five-year high for Total Current Liabilities was $23.9 million in Q2 2025, with the low at $15.5 million in Q1 2022.
- The 5-year median for Total Current Liabilities is $20.5 million (2023), against an average of $20.2 million.
- The sharpest annual moves came in 2022 and 2026: Total Current Liabilities soared 56.08% in 2022, then dropped 16.48% in 2026.
- Champions Oncology's Total Current Liabilities stood at $18.7 million in 2022, then gained by 11.82% to $21.0 million in 2023, then decreased by 9.97% to $18.9 million in 2024, then grew by 17.39% to $22.1 million in 2025, then slipped by 10.02% to $19.9 million in 2026.
- Business Quant data shows CSBR's Total Current Liabilities at $19.9 million in Q2 2026, $20.7 million in Q1 2026, and $22.1 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.51 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 438.74 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 630.93 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 2.49 Bn |
| 10 | Champions Oncology | 71.17 Mn | 71.17 Mn | 7.03 Mn | 19.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 19.92 Mn |
| Jan 31, 2026 | 20.68 Mn |
| Oct 31, 2025 | 22.14 Mn |
| Jul 31, 2025 | 22.70 Mn |
| Apr 30, 2025 | 23.85 Mn |
| Jan 31, 2025 | 19.87 Mn |
| Oct 31, 2024 | 18.86 Mn |
| Jul 31, 2024 | 19.16 Mn |
| Apr 30, 2024 | 21.54 Mn |
| Jan 31, 2024 | 21.97 Mn |
| Oct 31, 2023 | 20.95 Mn |
| Jul 31, 2023 | 20.38 Mn |
| Apr 30, 2023 | 21.73 Mn |
| Jan 31, 2023 | 20.80 Mn |
| Oct 31, 2022 | 18.74 Mn |
| Jul 31, 2022 | 16.62 Mn |
| Apr 30, 2022 | 17.48 Mn |
| Jan 31, 2022 | 15.50 Mn |
| Oct 31, 2021 | 12.47 Mn |
| Jul 31, 2021 | 11.68 Mn |